The mitochondria mediate the induction of NOX1 gene expression by aldosterone in an ATF-1-dependent manner

Cellular and Molecular Biology Letters

Volumn 16, Issue 2, 2011, Pages 226-235

  Fu, Yanping ^a   Shi, Gang ^b   Wu, Yong ^c   Kawai, Yasuyuki ^d   Tian, Qing ^a   Yue, Linlin ^a   Xia, Qinjie ^a   Miyamori, Isamu ^d   Fan, Chunyuan ^a,e  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c The second out patient institutions of Chengdu Military Region   (China)

^d UNIVERSITY OF FUKUI   (Japan)

^e Seventh People's Hospital   (China)

Author keywords

Aldosterone; ATF 1; Mitochondria; NOX1; VSMC

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 1; ALDOSTERONE; DIPHENYLIODONIUM SALT; MESSENGER RNA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1;

ANIMAL CELL; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; GENE; GENE EXPRESSION; GENE SILENCING; MITOCHONDRION; NONHUMAN; NOX1 GENE; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

RATTUS;

EID: 79953743324     PISSN: 14258153     EISSN: 16891392     Source Type: Journal    
DOI: 10.2478/s11658-011-0002-3     Document Type: Article

References (21)

1. Mazak, I., Fiebeler, A., Muller, D. N., Park, J. K., Shagdarsuren, E., Lindschau, C., Dechend, R., Viedt, C., Pilz, B., Haller, H. and Luft, F. C. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation109 (2004) 2792-2800.
2. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J. and Wittes, J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure, randomized aldactone evaluation study investigators. N. Engl. J. Med. 341 (1999) 709-717.
3. Zannad, F., Ella, F., Dousset, B., Perez, A. and Pitt, B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES), Rales Investigators. Circulation102 (2000) 2700-2706.
4. Irani, K. Oxidant signaling in vascular cell growth, death, and survival: a review of the roles of reactive oxygen species in smooth muscle and endothelial cell mitogenic and apoptotic signaling. Circ. Res. 87 (2000) 179-183.
5. Griendling, K. K., Sorescu, D. and Ushio-Fukai, M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86 (2000) 449-501.
6. Suh, Y. A., Arnold, R. S., Lassegue, B., Shi, J., Xu, X., Sorescu, D., Chung, A. B., Griendling, K. K. and Lambeth, J. D. Cell. transformation by the superoxide-generating oxidase Mox1. Nature401 (1999) 79-82.
7. Lassegue, B., Sorescu, D., Szocs, K., Yin, Q., Akers, M., Zhang, Y., Grant, S. L., Lambeth, J. D. and Griendling, K. K. Griendling, Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ. Res. 88 (2001) 858-860.
8. Katsuyama, M., Fan, C., Arakawa, N., Nishinaka, T., Miyagishi, M., Taira, K. and Yabe-Nishimura, C. Essential role of ATF-1 in induction of NOX1, a catalytic subunit of NADPH oxidase: involvement of mitochondrial respiratory chain. Biochem. J. 386 (2005) 255-261.
9. Matsuno, K., Yamada, H., Iwata, K., Jin, D., Katsuyama, M., Matsuki, M., Takai, S., Yamanish, K., Miyazaki, M., Matsubara, H. and Yabe-Nishimur, C. A Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation112 (2005) 2677-2685.
10. Nishinaka, T. and Yabe-Nishimura, C. EGF receptor-ERK pathway is the major signaling pathway that mediates upregulation of aldose reductase expression under oxidative stress. Free Radic. Biol. Med. 31 (2001) 205-216.
11. Miyagishi, M. and Taira, K. U6 promoter-driven siRNAs with four uridine 3'overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotechnol. 20 (2002) 497-500.
12. Yokota, T., Sakamoto, N., Enomoto, N., Tanabe, Y., Miyagishi, M., Maekawa, S., Yi, L., Kurosaki, M., Taira, K., Watanabe, M. and Mizusawa, H. Inhibition of intracellular hepatitis C virus replication by synthetic and vector-derived small interfering RNAs. EMBO. Rep. 4 (2003) 602-608.
13. Li, Y. and Trush, M. A. Diphenyleneiodonium, an NAD(P)H oxidase inhibitor, also potently inhibits mitochondrial reactive oxygen species production. Biochem. Biophys. Res. Commun. 253 (1998) 295-299.
14. Montminy, M. R., Sevarino, K. A., Wagner, J. A., Mandel, G. and Goodman, R. H. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. Proc. Natl. Acad. Sci. USA83 (1986) 6682-6686.
15. Katsuyama, M., Fan, C. and Yabe-Nishimura, C. NADPH oxidase is involved in prostaglandin F2alpha-induced hypertrophy of vascular smooth muscle cells: induction of NOX1 by PGF2alpha. J. Biol. Chem. 277 (2002) 13438-13442.
16. Katsuyama, M., Cevik, M. O., Arakawa, N., Kakehi, T., Nishinaka, T., Iwata, K., Ibi, M., Matsuno K. and Nishimura, C. Y. Myocyte enhancer factor 2B is involved in the inducible expression of NOX1/NADPH oxidase, a vascular superoxide-producing enzyme. FEBS J. 274 (2007) 5128-5136.
17. Lee, S. B., Bae, I. H., Bae, Y. S. and Um, H. D. Link between mitochondria and NADPH oxidase 1 isozyme for the sustained production of reactive oxygen species and cell death. J. Biol. Chem. 281 (2006) 36228-36235.
18. Young, M. and Funder, J. Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis Endocrinology144 (2003) 3848-3851.
19. Lombes, M., Oblin, M. E., Gasc, J. M., Baulieu, E. E., Farman, N. and Bonvalet, J. P. Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ. Res. 71 (1992) 503-510.
20. Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin B. L., Housman, D. E. and Evans, R. M. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science237 (1987) 268-275.
21. Losel, R. M., Feuring, M., Falkenstein, E. and Wehling, M. Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids67 (2002) 493-498.